Evento

Symposium on Pathogen Inactivation

Preliminary Program:
1:00-2:40 pm PT
Formal presentations
The FDA approval of pathogen-reduced platelets and related issues including: pathogen inactivation technology, efficacy, safety, cost and legal implications from both hospital and blood center perspective. FDA draft guidance for bacterial testing.
Edward Snyder, MD, FACP, Professor Laboratory Medicine, Yale University Medical School; Director, Transfusion/Apheresis/Tissue/Cell Processing Services, Yale-New Haven Hospital
Louis M. Katz MD, Chief Medical Officer, America's Blood Centers
Irene M. Hecht, Attorney at Law

2:40 to 3:30 pm PT
Panel Discussion
Edward Snyder, MD, FACP, Professor Laboratory Medicine, Yale University Medical School Director, Transfusion/Apheresis/Tissue/Cell Processing Services, Yale-New Haven Hospital
Louis M. Katz MD, Chief Medical Officer, America's Blood Centers
Irene M. Hecht, JD, Attorney at Law
Richard J Benjamin, MD, PhD, FRCPath, Chief Medical Officer, American Red Cross
Sherrill J. Slichter, MD, Director, Platelet Transfusion Research, Bloodworks Northwest Research Institute
James P. AuBuchon, MD, FCAP, FRCP(Edin), President & CEO, Bloodworks Northwest

3:30-4:30 pm PT:
Closing remarks/wrap up
For interested participants: Clinical trial opportunities
Laurence Corash, MD, Chief Medical and Scientific Officer, Senior Vice President Medical Affairs, Cerus Corporation
Ray Goodrich, Ph.D., Vice President of Scientific and Clinical Affairs, Terumo BCT